Conexeu Sciences Inc. (CNXU)

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026

UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine

Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine